
The June 24, 2004 checkwrite date has changed to June 22, 2004. The electronic cut-off date for this checkwrite will remain June 18, 2004.
EDS, 1-800-688-6696 or 919-851-8888
In April 2004, the Department of Health and Human Services (DHHS) awarded the contract for the replacement of the North Carolina Medicaid Management Information System (NCMMIS) to ACS State Healthcare, LLC (ACS). ACS has extensive experience in delivering fiscal agent services. Their proposed base Medicaid system has been successfully implemented in four other states. Operations of the new NCMMIS are scheduled to begin no later than June 2006.
DHHS is fully committed to ensuring a smooth transition to the new fiscal agent contract. Following are some of the prudent measures being taken to avoid an adverse impact on provider reimbursement:
With the ACS system, providers can continue to submit claims using current methods or by utilizing new web portal capabilities for claims submission with real-time adjudication, claims correction or inquiry, and the ability to void and adjust processed claims.
Providers who would like to participate in the user acceptance phase of the implementation process may e-mail Vivian.williamson@ncmail.net with their interest. Please indicate your provider type (e.g., physician, hospital, pharmacy, long-term care facility, etc.) in the subject line of your message.
Portia Asbridge, Communications Manager
NCMMIS+ Initiative, 919-855-3161
Effective with claims processed on or after July 1, 2004, Medicaid will deny claims for recipients age 65 and over who are entitled to Medicare benefits but fail to enroll. Providers may bill the recipient for Medicare covered services if they fail to enroll with Medicare. Medicaid recipients age 65 and older who are eligible for Medicare received notice with their June Medicaid card that they must enroll or the provider may bill them. Claims will be denied with EOB #1001, "Recipient is entitled to Medicare but failed to enroll. Bill the recipient."
Except for legal aliens who have not lived in the United States for five consecutive years, all Medicaid recipients age 65 or older are required to apply for Medicare coverage. Medicaid pays the Medicare Part B premium for Medicare-eligible recipients through the buy-in program.
If you determine that the recipient is not entitled to Medicare benefits because he/she is under age 65 or because he/she is a legal alien who has not lived in the United States for five years or more, submit a copy of the claim with documentation of age or alien status to:
Division of Medical Assistance
Claims Analysis Unit
2501 Mail Service Center
Raleigh, NC 27699-2501
The Division of Medical Assistance will determine if Medicaid payment can be made for these individuals.
Claims Analysis Unit
DMA, 919-855-4045
The seminars and teleconferences for the Medicaid Family Planning Waiver program scheduled for June 2004 and July 2004 have been cancelled due to a delay in the implementation of the Waiver program.
Providers will be notified through the general Medicaid bulletin of the new implementation date and the new schedule for the seminars and teleconferences.
EDS, 1-800-688-6696 or 919-851-8888
The following memo was issued by Jeffrey Engel, M.D., State Epidemiologist, and Lou F. Turner, Director, State Laboratory of Public Health on May 10, 2004 to all North Carolina physicians and laboratory service providers.
As we enter the summer season of 2004, the N.C. Division of Public Health is seeking your assistance in identifying and diagnosing suspected cases of arboviral encephalitis. In 2003, North Carolina reported 24 human cases of LaCrosse (LAC) encephalitis, 22 cases of West Nile Virus (WNV) infection, and 1 case of Eastern Equine encephalitis (EEE). In addition, hundreds of horses across the state were diagnosed with either WNV or EEE.
WNV is now endemic across North Carolina and primarily affects adults, whereas LAC is localized to the western region and primarily affects children. Human disease from both WNV and LAC peaks in late August and early September. Human EEE is rare in North Carolina. Recall that symptomatic WNV infection ranges from WNV fever (headache, lymphadenopathy, nausea, vomiting, and fatigue) to WNV neuroinvasive disease (meningitis, encephalitis, and /or acute flaccid paralysis resembling Guillian-Barre syndrome). Head CT scans are normal and brain MRI scans may show leptomeningeal enhancement. EMG studies show axonal degeneration and demyelination, not typical of Guillain-Barre. Cerebrospinal fluid analysis is consistent with aseptic meningitis with an elevated protein, normal glucose, and pleocytosis. Neuroinvasive disease is more common in people over age 50.
Specific laboratory arbovirus testing is available free at the State Laboratory for Public Health in Raleigh for patients manifesting clinical syndromes associated with arboviral infections. We encourage you to use the State Lab since it will expedite our public health surveillance efforts. Serum specimens should be sent for antibody detection during the acute illness. Acute CSF for antibody detection, if desired, must be accompanied by a companion serum collected at approximately the same time. For confirmation of probable cases, convalescent serum should be sent 2 to 3 weeks after onset of illness or at the time of hospital discharge. Samples should be sent with a completed form available on the web at http://slph.state.nc.us. Click on "West Nile Virus/Testing" to download the forms. Tests on hospitalized patients may be ordered as an "Arbovirus Panel" since the State Lab will automatically test for all mosquito-borne viral encephalitides. (Molecular testing of acute phase sera or CSF has been proven to be of little value for WNV and other mosquito-borne viruses.)
Your cooperation is appreciated. We understand that forms and convalescent samples are burdensome, however your efforts are needed for the health of your patients and the public at-large.
North Carolina State Laboratory Public Health website
Epidemiology Section
Division of Public Health, 919-733-3421
When a claim denies with an EOB related to eligibility, providers may be instructed to contact the Division of Medical Assistance’s Claims Analysis Unit for assistance. Effective May 25, 2004, the Claims Analysis Unit’s telephone number was changed to 919-855-4045. Providers should note this change for future reference.
Claims Analysis Unit
DMA, 919-855-4045
Changes have been made to Attachment A: Completing the Certificate of Medical Necessity and Prior Approval Form of Medical Coverage Policy #5, Durable Medical Equipment. The instructions for completing the "FROM DATE" and "TO DATE" in Block 26 have been changed for DME-related supplies. These supplies are now entered on the Certificate of Medical Necessity and Prior Approval form in the same manner as national miscellaneous HCPCS codes A9900 and B9998. Thus, the instructions for FROM DATE and TO DATE are as follows:
Customized Equipment, Prosthetics and Orthotics: Enter the date of the physician's prescription in the FROM block. Enter a date six months after the FROM date in the TO block.
Other Purchased Equipment: Enter the date the item is expected to be delivered to the recipient in the FROM block. Enter a date six months after the FROM date in the TO block.
Rental Equipment: Enter the anticipated beginning of the rental period in the FROM block. Enter the expected end of the rental period in the TO block.
Service and Repairs: Enter the expected date that the item is to be serviced or repaired in the FROM block. Enter a date three months after the FROM date in the TO block.
DME-Related Supplies and National Miscellaneous HCPCS Codes A9900 and B9998: Enter the date that the item is expected to be delivered to the recipient in the FROM block. Enter a date one year after the FROM date in the TO block if the prescribing physician, physician’s assistant or nurse practitioner writes the prescription for a year. Otherwise, the TO date must be the last effective date of the prescription. (The maximum length of time for the FROM date to the TO date must be one year.)
Medical Coverage Policy #5, Durable Medical Equipment
EDS, 1-800-688-6696 or 919-851-8888
Developmental screening, including mental, emotional, and behavioral, is one of the many components of a complete Health Check visit. The current Health Check Billing Guide stipulates that three written developmental assessments should be performed: the first by 12 months, the second by 24 months, and the third by 60 months.
Effective July 1, 2004, Health Check screenings will require the use of a formal, standardized tool for developmental screening. The American Academy of Pediatrics Committee on Children with Disabilities recommends the use of standardized screening tests at well child visits.
The N.C. Pediatric Society has endorsed the following schedule for formal standardized developmental screenings: 6 months; 12 months; 18 or 24 months; and 3, 4, and 5 years of age. Developmental screening results must be documented in the medical record.
The developmental screening CPT code 96110 appended with the EP modifier must be listed in addition to the preventive medicine CPT codes. For additional information, please refer to the April 2004 Special Bulletin I, Health Check Billing Guide 2004.
Several primary care practices in North Carolina, with two different demonstrations projects, have put standardized screening tools "to the test" and have successfully integrated developmental screening and surveillance into their office workflow. To learn more about what is practical and what works contact Curtis Honeycutt at Curtis.Honeycutt@ncmail.net.
Tammy Schneider, Health Check
DMA, 919-857-4022
Effective with date of service May 1, 2004, the maximum allowable rate for the following hospice services has increased. The hospice rates are as follows:
|
Hospice ICF Care (Room and Board) |
Hospice SNF Care (Room and Board) |
||
|---|---|---|---|
|
Metropolitan Statistical Area |
SC |
RC 658 |
RC 659 |
|
Asheville |
39 |
$ 131.14 |
$ 131.14 |
|
Charlotte/Gastonia/Rock Hill |
41 |
131.14 |
131.14 |
|
Fayetteville |
42 |
131.14 |
131.14 |
|
Greensboro/Winston-Salem/High Point |
43 |
131.14 |
131.14 |
|
Hickory/Morganton/Lenoir |
44 |
131.14 |
131.14 |
|
Jacksonville |
45 |
131.14 |
131.14 |
|
Raleigh/Durham/Chapel Hill |
46 |
131.14 |
131.14 |
|
Wilmington |
47 |
131.14 |
131.14 |
|
Rural counties |
53 |
131.14 |
131.14 |
|
Goldsboro |
105 |
131.14 |
131.14 |
|
Greenville |
106 |
131.14 |
131.14 |
|
Norfolk (Currituck County) |
107 |
131.14 |
131.14 |
|
Rocky Mount |
108 |
131.14 |
131.14 |
Note: At this time, the rates for RC651, RC 652, RC 655, and RC 656 have not changed. Providers may refer to the December 2003 general Medicaid bulletin for the most current rates.
Key to Hospice Rate Table
Note: Providers must bill their usual and customary charges. Adjustments will not be accepted for rate changes.
Reimbursement Rate Increase for Hospice Services, December 2003 Medicaid Bulletin
Carolyn Brown, Financial Operations
DMA, 919-857-4015
This article is reprinted with permission from the North Carolina Hospital Association and the National Uniform Billing Committee.
The patient’s discharge status (Form Locator 22) is required on all institutional claims –inpatient, outpatient, hospice, home care, etc. Identifying the appropriate code is often confusing, as can be seen by the following questions and answers. A basic rule of thumb is to code to the highest level of care that is known. For example, an individual discharged to home with a home health plan of care is coded as 06, rather than 01.
For additional information from the National Uniform Billing Committee about the use of patient discharge status codes, send an e-mail to tomundson@aha.org.
EDS, 1-800-688-6696 or 919-851-8888
The intrauterine devices (IUDs) listed in the table below are covered by the N.C. Medicaid program. These can be billed on the CMS-1500 claim form. The new maximum reimbursement rates are effective with date of service June 1, 2004.
|
Procedure Code |
Description |
Maximum Reimbursement Rate |
|---|---|---|
|
J7300 |
Intrauterine Copper Contraceptive (Paragard T380A) |
$ 358.80 |
|
J7302 |
Levonorgestrel-releasing intrauterine contraceptive system, 52 mg (Mirena) |
471.88 |
Providers must bill their usual and customary rates.
EDS, 1-800-688-6696 or 919-851-8888
Maternity Care Coordination Services seminars are scheduled for July 2004. The site locations and dates for the seminars are listed below. Because new policy guidelines will be implemented on August 1, 2004, attendance at these seminars is mandatory for both current and new Maternity Care Coordinators.
Preregistration is required. Providers may register for the seminars by completing and submitting the Maternity Care Coordination Services Seminar registration form or through online registration. Please indicate on the registration form the number of staff who will be attending and the session you plan to attend. Seminars are scheduled to begin at 10:00 a.m. and end at 1:00 p.m. or earlier. Lunch will not be served. Providers are encouraged to arrive by 9:45 a.m. to complete registration.
The seminars will use the July 2004 Special Bulletin IV, Maternity Care Coordination Services, as the primary handout for the session. Providers must access and print the PDF version of the special bulletin and bring it to the session. The special bulletin will be available on July 1, 2004.
|
Wednesday, July 7, 2004 |
Thursday, July 8, 2004 |
|
Tuesday, July 13, 2004 |
Wednesday, July 14, 2004 |
Blue Ridge Community College, Bo Thomas Auditorium - Flat Rock
Take I-40 to Asheville. Travel east on I-26 to exit 22. Turn right and then take the next right. Follow the signs to Blue Ridge Community College. Turn left at the large Blue Ridge Community College sign. The college is located on the right. Take the first right-hand turn into the parking lot for the Bo Thomas Auditorium.
Greenville Hilton - Greenville
Jane S. McKimmon Center - Raleigh
Holiday Inn Conference Center - Salisbury
Traveling South on I-85
Take exit 75. Turn right onto Jake Alexander Boulevard. Travel approximately
½ mile. The Holiday Inn is located on the right.
Traveling North on I-85
Take exit 75. Turn left onto Jake Alexander Boulevard. Travel approximately
½ mile. The Holiday Inn is located on the right.
Effective with date of service June 1, 2004, the N.C. Medicaid program covers bevacizumab (Avastin) for use in the Physician’s Drug Program. Avastin, in combination with intravenous 5-fluorouracil-based chemotherapy, is indicated for the first-line treatment of patients with metastatic colorectal carcinoma. The FDA’s recommended dosing schedule is 5 mg/kg once every 14 days as an IV infusion until disease progression is detected.
The ICD-9-CM diagnosis codes required when billing for Avastin are:
V58.1 – admission or encounter for chemotherapy
and
a diagnosis code in the range of 153.0 through 154.8
Providers must bill J9999, the unclassified drug code for antineoplastic agents, with an invoice attached to the CMS-1500 claim form. An invoice must be submitted with each claim. The paper invoice must indicate the recipient’s name and Medicaid identification number, the name of the medication, the dosage given, the National Drug Code (NDC) number from the vial(s) used, the number of vials used, and the cost per dose.
Providers must indicate the number of units given in block 24G on the CMS-1500 claim form. For Medicaid billing, one unit of coverage is the 4 ml vial. The maximum reimbursement rate per unit is $584.38. Providers must bill their usual and customary charge.
Add this drug to the list of injectable drugs published in the April 2004 general Medicaid bulletin.
EDS, 1-800-688-6696 or 919-851-8888
Effective with date of service June 1, 2004, the N.C. Medicaid program covers cetuximab (Erbitux) for use in the Physician’s Drug Program. Erbitux, a human/mouse chimeric monoclonal antibody, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Erbitux administered as a single agent, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.
The FDA-approved dose of Erbitux in combination with irinotecan or as monotherapy, is 400 mg/m2 as an initial loading dose (first infusion) administered as a 120-minute IV infusion (maximum infusion rate 5 ml per minute). The recommended weekly maintenance dose is 250 mg/m2 over 60 minutes (maximum infusion rate 5 ml per minute).
The ICD-9-CM diagnosis codes required when billing for Erbitux are:
V58.1 – admission or encounter for chemotherapy
and
a diagnosis code in the range of 153.0 through 154.8
Providers must bill J9999, the unclassified drug code for antineoplastic agents, with an invoice attached to the CMS-1500 claim form. An invoice must be submitted with each claim. The paper invoice must indicate the recipient’s name and Medicaid identification number, the name of the medication, the dosage given, the National Drug Code (NDC) number from the vial(s) used, the number of vials used, and the cost per dose.
Providers must indicate the number of units given in block 24G on the CMS-1500 claim form. For Medicaid billing, one unit of coverage is the 100 mg/50 ml vial. The maximum reimbursement rate per unit is $489.60. Providers must bill their usual and customary charge.
Add this drug to the list of injectable drugs published in the April 2004 general Medicaid bulletin.
EDS, 1-800-688-6696 or 919-851-8888
Effective with date of service June 1, 2004, the N.C. Medicaid program covers pemetrexed (Alimta) for use in the Physician’s Drug Program. Alimta is an antifolate, antineoplastic agent. The FDA states that, in combination with cisplatin, it is indicated for the first-line treatment of patients with malignant pleural mesothelioma, whose disease is either unresectable or who are otherwise not candidates for curative surgery. The FDA indicates that the usual adult dose is 500 mg/m2 infused over 10 minutes on day 1 of each 21-day cycle.
The ICD-9-CM diagnosis codes required when billing for Alimta are:
V58.1 – admission or encounter for chemotherapy
and
a diagnosis code in the range of 163.0 through 163.8
Providers must bill J9999, the unclassified drug code for antineoplastic agents, with an invoice attached to the CMS-1500 claim form. An invoice must be submitted with each claim. The paper invoice must indicate the recipient’s name and Medicaid identification number, the name of the medication, the dosage given, the National Drug Code (NDC) number from the vial(s) used, the number of vials used, and the cost per dose.
Providers must indicate the number of units given in block 24G on the CMS-1500 claim form. For Medicaid billing, one unit of coverage is 500 mg. The maximum reimbursement rate per unit is $2,071.88. Providers must bill their usual and customary charge.
Add this drug to the list of injectable drugs published in the April 2004 general Medicaid bulletin.
EDS, 1-800-688-6696 or 919-851-8888
Effective July 1, 2004, the Division of Medical Assistance will no longer accept or review retroactive records for admission. It is the nursing facility’s responsibility to obtain prior approval for all residents upon admission. EDS will continue to review requests for retroactive approval back to 90 days. EDS will only review retroactive requests back to 180 days where eligibility is an issue.
EDS, 1-800-688-6696 or 919-851-8888
On May 10, 2004, the Division of Medical Assistance (DMA) implemented the new nursing facility reimbursement methodology third quarter reimbursement rates as directed by N.C. General Assembly House Bill 397 10.28. These rates are effective with dates of service May 1, 2004. Claims submitted for dates of service May 1, 2004 and after will automatically be reimbursed under the new case mix system rates utilizing the final facility roster snapshot date of December 31, 2003 – Avg. CMI for Medicaid residents.
Until otherwise notified, all providers must continue to bill using the level of care approved on the FL-2. New provider rates are currently being paid on both levels of care. For example, if the resident’s last approval was for ICF level of care, then the provider must use an ICF provider number and an ICF bill type. Providers will be notified of changes to this process in a future general Medicaid bulletin.
For an updated version of the Prospective Reimbursement Plan for Nursing Care Facilities, refer to Attachment 4.19-D, page 1 through 4.19-D, page 28 of the State Plan. The new case mix methodology reimbursement system is supported by a provider assessment and through the implementation of the new rates as a part of the ongoing operations process.
The provider assessment component also becomes effective on May 1, 2004.
Note: The May 2004 provider assessment and report are due to DMA no later than June 15, 2004. Failure to submit the assessment in a timely manner will result in recoupment and penalties per the Department of Health and Human Services’ Controller Case Management Plan.
Please contact DMA’s Nursing Facility Rate Setting staff at 919-857-4015 with questions about the provider assessment worksheet or reimbursement rates. For billing questions, please contact EDS at 1-800-688-6696 or 919-851-8888.
Financial Operations
DMA, 919-857-4015
The April 2004 general Medicaid bulletin published an article listing the FDA-approved drugs currently covered by the N.C. Medicaid program when the drugs are provided in a physician’s office for the FDA-approved indications. Rates were effective with date of service April 1, 2004. Please make the following additions/corrections to that list.
|
Invoice Required |
Procedure Code |
Description |
Maximum Reimbursement Rate |
|---|---|---|---|
|
J0475 |
Baclofen, Kit 1(one) 20 ml. Amp. (10 mg/20 ml. 500 mcg/ml |
$ 209.10 |
|
|
* |
J3490 |
Baclofen, Kit 2 (two) 5 ml. Amp. (10 mg/5 ml. 2000 mcg/ml) |
438.60 |
|
* |
J3490 |
Baclofen, Kit 4 (four) 5 ml. Amp. (10 mg/5 ml. 2000 mcg/ml.) |
770.10 |
|
J0476 |
Baclofen, for intrathecal trial, 50 mcg (Lioresal for intrathecal trial) |
71.40 |
|
|
* |
J3490 |
Risperdone 25 mg (Risperdal Consta) |
235.96 |
|
* |
J3490 |
Risperdone 37.5 mg (Risperdal Consta) |
353.95 |
|
* |
J3490 |
Risperdone 50 mg (Risperdal Consta) |
471.93 |
Physicians will continue to bill on the CMS-1500 claim form using the appropriate drug code and indicating the specified number of units administered. Providers must bill their usual and customary charges.
(*) Designates that an invoice must be submitted with each CMS-1500 claim form. The paper invoice must indicate the name of the recipient, the recipient’s Medicaid identification number, the name of the medication, the dosage given, the National Drug Code (NDC) number from the vial(s) used, the number of vials used, and the cost per dose. Providers must indicate the number of units given in block 24G on the CMS-1500 claim form. Payment is based in accordance with Medicaid’s State Plan for reimbursement. Providers will be reimbursed the lower of the invoice price or maximum allowable fee on file.
EDS, 1-800-688-6696 or 919-851-8888
The Division of Medical Assistance has laboratory panel audits in place that replicate the Correct Coding Initiative (CCI) audits. The CCI has two types of audits: mutually exclusive and bundling. Mutually exclusive codes are combinations of codes not expected to be performed in conjunction with each other on the same date of service. The CCI bundling audits designate which components of a comprehensive code cannot be reimbursed when billed on the same date of service as the comprehensive code. These audits will sometimes allow a modifier, appended to the component code, to bypass the audit. Modifiers can be used to designate that a procedure was a completely separate service performed in addition to a basic service. The decision as to whether a modifier is allowed is set within the CCI audit.
The following laboratory panel audits are in place.
|
Comprehensive Panel Code |
Component Code |
|---|---|
|
80048 |
82310, 82374, 82435, 82565, 82947, 84132, 84295, 84520, 80051 |
|
80051 |
82374, 82435, 84132, 84295 |
|
80053 |
80048, 80051, 80069, 80076, 82040, 82247,82310, 82374, 82435, 82565, 82947, 84075,84132, 84155, 84295, 84450, 84460, 84520 |
|
80061 |
80500, 80502, 82465, 83718, 83721, 84478 |
|
80069 |
80048, 80051, 82040, 82310, 82374, 82435, 82565, 82947, 84100, 84132, 84295, 84520 |
|
80074 |
86705, 86709, 86803, 87340 |
|
80076 |
82040, 82247, 82248, 84075, 84155, 84450, 84460 |
EDS, 1-800-688-6696 or 919-851-8888
Effective with date of service May 1, 2004, the maximum allowable rate for the following swing beds and lower levels of care services has been modified. The swing beds and lower levels of care rates are as follows:
|
Swing Beds and Lower Levels of Care (Room and Board) |
Specialty 086 |
Specialty 086 |
Specialty 086 |
Specialty 086 |
|---|---|---|---|---|
|
Type |
15 (INC) |
16 (SNC) |
17 (H-INC) |
18 (H-SNC) |
|
004 |
$ 121.57 |
$ 121.57 |
$ 121.57 |
$ 121.57 |
|
008 |
121.57 |
121.57 |
121.57 |
121.57 |
|
059 |
121.57 |
121.57 |
121.57 |
121.57 |
|
060 |
121.57 |
121.57 |
121.57 |
121.57 |
|
063 |
121.57 |
121.57 |
121.57 |
121.57 |
|
068 |
121.57 |
121.57 |
121.57 |
121.57 |
|
069 |
121.57 |
121.57 |
121.57 |
121.57 |
|
076 |
121.57 |
121.57 |
121.57 |
121.57 |
|
090 |
121.57 |
121.57 |
121.57 |
121.57 |
Note: At this time, swing beds and lower levels of care (INC, SNC, H-INC, and H-SNC) are reimbursed at the same rate.
Providers must bill their usual and customary charges. Adjustments will not be accepted for rate changes.
Carolyn Brown, Financial Operations
DMA, 919-857-4015
In accordance with Session Law 2003-284, proposed new or amended Medicaid medical coverage policies are available for review and comment on DMA’s website at http://www.dhhs.state.nc.us/dma/mp/proposedmp.htm. To submit a comment related to a policy, refer to the instructions on the website. Providers without Internet access can submit written comments to the address listed below.
Darlene Creech
Division of Medical Assistance
Medical Policy Section
2501 Mail Service Center
Raleigh, NC 27699-2501
The initial comment period for each proposed policy is 45 days. An additional 15-day comment period will follow if a proposed policy is revised as a result of the initial comment period.
|
June 8, 2004 |
July 12, 2004 |
August 10, 2004 |
|
June 15, 2004 |
July 20, 2004 |
August 17, 2004 |
|
June 22, 2004 |
July 29, 2004 |
August 26, 2004 |
|
June 29, 2004 |
|
June 4, 2004 |
July 9, 2004 |
August 6, 2004 |
|
June 11, 2004 |
July 16, 2004 |
August 13, 2004 |
|
June 18, 2004 |
July 23, 2004 |
August 20, 2004 |
|
June 25, 2004 |
Electronic claims must be transmitted and completed by 5:00 p.m. on the cut-off date to be included in the next checkwrite. Any claims transmitted after 5:00 p.m. will be processed on the second checkwrite following the transmission date.
|
_____________________
|
_____________________
|
|
|
Gary H. Fuquay, Director
|
Cheryll Collier
|
|
|
Division of Medical Assitance
|
Executive Director
|
|
|
Department of Health and Human Services
|
EDS
|
| DMA Home | Top |